After a delay, the Alpha-3 study faces an April futility analysis.
ApexOnco Front Page
Recent articles
A first-in-human trial of PRT12396 starts next month.
New detalimogene bladder cancer data send the minnow’s stock up 47%.
The response rate jumps to 30% with higher doses of IMA402.
Bezuclastinib plus Sutent could become standard of care in second-line GIST.
After more discontinuations, a new deal brings in fresh blood.
The CD70-targeting CTX131 heads for the scrapheap.
Harmoni-A hits, backing a quiet disclosure about the Harmoni trial.
